Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Condition aggravated? 16,616 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 16,616 reports of Condition aggravated have been filed in association with INFLIXIMAB (Renflexis). This represents 11.9% of all adverse event reports for INFLIXIMAB.

16,616
Reports of Condition aggravated with INFLIXIMAB
11.9%
of all INFLIXIMAB reports
1,624
Deaths
5,325
Hospitalizations

How Dangerous Is Condition aggravated From INFLIXIMAB?

Of the 16,616 reports, 1,624 (9.8%) resulted in death, 5,325 (32.0%) required hospitalization, and 2,026 (12.2%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for INFLIXIMAB. However, 16,616 reports have been filed with the FAERS database.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173) Intentional product use issue (11,028)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627) TOCILIZUMAB (8,471)

Which INFLIXIMAB Alternatives Have Lower Condition aggravated Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated INFLIXIMAB Demographics